ATE469640T1 - Stabile pharmazeutische zusammensetzungen von zonisamide und verfahren zur deren herstellung - Google Patents
Stabile pharmazeutische zusammensetzungen von zonisamide und verfahren zur deren herstellungInfo
- Publication number
- ATE469640T1 ATE469640T1 AT06250301T AT06250301T ATE469640T1 AT E469640 T1 ATE469640 T1 AT E469640T1 AT 06250301 T AT06250301 T AT 06250301T AT 06250301 T AT06250301 T AT 06250301T AT E469640 T1 ATE469640 T1 AT E469640T1
- Authority
- AT
- Austria
- Prior art keywords
- zonisamide
- stable
- pharmaceutical composition
- stable zonisamide
- capsule
- Prior art date
Links
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical group C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 title abstract 9
- 229960002911 zonisamide Drugs 0.000 title abstract 9
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 abstract 5
- 238000005469 granulation Methods 0.000 abstract 2
- 230000003179 granulation Effects 0.000 abstract 2
- 239000011872 intimate mixture Substances 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000005056 compaction Methods 0.000 abstract 1
- 238000003801 milling Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64503005P | 2005-01-21 | 2005-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469640T1 true ATE469640T1 (de) | 2010-06-15 |
Family
ID=36130027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06250301T ATE469640T1 (de) | 2005-01-21 | 2006-01-20 | Stabile pharmazeutische zusammensetzungen von zonisamide und verfahren zur deren herstellung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060188569A1 (de) |
| EP (1) | EP1683516B1 (de) |
| JP (1) | JP2008523109A (de) |
| CN (1) | CN101166516A (de) |
| AT (1) | ATE469640T1 (de) |
| AU (1) | AU2006206292B2 (de) |
| CA (1) | CA2595483A1 (de) |
| DE (1) | DE602006014607D1 (de) |
| ES (1) | ES2344574T3 (de) |
| IL (1) | IL183377A0 (de) |
| WO (1) | WO2006078948A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1558582B1 (de) | 2003-07-22 | 2005-12-21 | Arena Pharmaceuticals, Inc. | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| CN102065858B (zh) * | 2008-04-29 | 2014-07-02 | 法奈科斯公司 | 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物 |
| TR201805216T4 (en) | 2008-10-28 | 2018-06-21 | Arena Pharm Inc | COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| CN102329278A (zh) * | 2010-07-13 | 2012-01-25 | 深圳市资福药业有限公司 | 一种唑尼沙胺晶体、其制备方法和包含其的药物组合物 |
| CN105050708A (zh) | 2012-11-14 | 2015-11-11 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| HK1245660A1 (zh) | 2015-06-12 | 2018-08-31 | Axovant Sciences Gmbh | 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物 |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| WO2019038584A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | An oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
| CN111419810B (zh) * | 2020-04-29 | 2022-02-11 | 南京长澳医药科技有限公司 | 一种高稳定性培哚普利叔丁胺片剂及其制备方法 |
| EP3928771A1 (de) | 2020-06-23 | 2021-12-29 | Laboratorios Lesvi, S.L. | Pharmazeutische zusammensetzungen von 1,2-benzisoxazol-3-methansulfonamid |
| JP7678106B2 (ja) * | 2020-12-01 | 2025-05-15 | エルジー・ケム・リミテッド | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む安定した経口用製剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63150220A (ja) * | 1986-12-15 | 1988-06-22 | Dainippon Pharmaceut Co Ltd | 経口用固形製剤の製造方法 |
| JPH0296516A (ja) * | 1988-09-29 | 1990-04-09 | Dainippon Pharmaceut Co Ltd | 粒剤およびその製造方法 |
| US5082669A (en) * | 1989-07-20 | 1992-01-21 | Dainippon Pharmaceutical Co., Ltd. | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked |
| US6342515B1 (en) * | 1997-12-26 | 2002-01-29 | Dainippon Pharmaceutical Co., Ltd. | Remedy for neurodegenerative diseases |
| EP1272181A2 (de) * | 2000-04-13 | 2003-01-08 | Synthon B.V. | Arzneizubereitungen mit gesteuerter wirkstoffabgabe enthaltend ein hypnotikum |
| EP1332363A4 (de) * | 2000-10-09 | 2007-08-29 | Kay Double | Nachweis neurodegenerativer erkrankungen |
| WO2004063174A1 (en) * | 2003-01-13 | 2004-07-29 | Dainippon Pharmaceutical Co., Ltd. | Process for the preparation of 1,2-dichloroethane free crystals of zonisamide and the highly pure crystals of zonisamide |
-
2006
- 2006-01-20 CA CA002595483A patent/CA2595483A1/en not_active Abandoned
- 2006-01-20 EP EP06250301A patent/EP1683516B1/de not_active Expired - Lifetime
- 2006-01-20 CN CNA2006800093620A patent/CN101166516A/zh active Pending
- 2006-01-20 US US11/336,546 patent/US20060188569A1/en not_active Abandoned
- 2006-01-20 ES ES06250301T patent/ES2344574T3/es not_active Expired - Lifetime
- 2006-01-20 DE DE602006014607T patent/DE602006014607D1/de not_active Expired - Lifetime
- 2006-01-20 AT AT06250301T patent/ATE469640T1/de not_active IP Right Cessation
- 2006-01-20 AU AU2006206292A patent/AU2006206292B2/en not_active Expired - Fee Related
- 2006-01-20 JP JP2007545749A patent/JP2008523109A/ja active Pending
- 2006-01-20 WO PCT/US2006/002103 patent/WO2006078948A2/en not_active Ceased
-
2007
- 2007-05-24 IL IL183377A patent/IL183377A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1683516B1 (de) | 2010-06-02 |
| WO2006078948A3 (en) | 2007-01-25 |
| ES2344574T3 (es) | 2010-08-31 |
| DE602006014607D1 (de) | 2010-07-15 |
| EP1683516A3 (de) | 2006-08-23 |
| JP2008523109A (ja) | 2008-07-03 |
| EP1683516A2 (de) | 2006-07-26 |
| CN101166516A (zh) | 2008-04-23 |
| US20060188569A1 (en) | 2006-08-24 |
| WO2006078948B1 (en) | 2007-03-01 |
| CA2595483A1 (en) | 2006-07-27 |
| IL183377A0 (en) | 2007-09-20 |
| WO2006078948A2 (en) | 2006-07-27 |
| AU2006206292A1 (en) | 2006-07-27 |
| AU2006206292B2 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183377A0 (en) | Stable pharmaceutical formulations of zonisamide and methods for their manufacture | |
| PE20010133A1 (es) | NUEVAS COMPOSICIONES DE MEDICAMENTOS A BASE DE COMPUESTOS ANTICOLINERGICAMENTE ACTIVOS Y ß-MIMETICOS | |
| RU2004123624A (ru) | Сухие гранулированные композиции азитромицина | |
| PE20030476A1 (es) | Composiciones farmaceuticas de acido micofenolico | |
| UA110012C2 (uk) | Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну | |
| BR0215175A (pt) | Métodos para a granulação úmida de azitromicina | |
| EP1813274A4 (de) | Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung | |
| UA90708C2 (ru) | Таблетки с улучшенной дисперсностью лекарственного вещества | |
| JP2016164147A (ja) | エキス末 | |
| ATE424192T1 (de) | Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten | |
| CN101822673B (zh) | 一种含有伊潘立酮的固体药物组合物 | |
| TW200621310A (en) | A process for preparing formulations of lypophilic active substances by spray freeze drying | |
| HRP20100216T1 (hr) | Kruti farmaceutski pripravak koji sadrži irbesartan | |
| ES2221347T3 (es) | Procedimiento para la produccion de capsulas y de comprimidos de sustancias naturales de origen vegetal. | |
| KR20190080920A (ko) | 전통 중의학 조성물의 제제에서 멘톨의 함량을 측정하는 방법 | |
| NO20064240L (no) | Farmasoytiske forbindelser for oral administrasjon og fremgangsmate for fremstilling derav | |
| GB2595140A (en) | Flupentixol/melitracen pharmaceutical composition and preparation thereof | |
| KR20120017060A (ko) | 초임계 ｃｏ２ 함침 방법 | |
| UA80872C2 (uk) | Фармацевтична композиція, що містить як активну речовину платиновий комплекс, і спосіб її виготовлення | |
| RU2006119505A (ru) | Стабилизированная композиция азитромицина | |
| AR052952A1 (es) | Composiciones farmaceuticas de 3'-l-valina ester de beta-d-2'-c-metil-ribofuranosil citidina | |
| KR20200090858A (ko) | 페오놀 및 아포시닌을 포함하는 액체 제형 | |
| ATE478675T1 (de) | Tablettenzusammensetzung mit einem chinesischen orthodoxen medizinextrakt und herstellungsverfahren dafür | |
| HK1254722A1 (zh) | 门冬氨酸鸟氨酸的泡腾制剂 | |
| KR101330142B1 (ko) | 경구 투여용 조성물 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |